Quantcast

Latest Anti-diabetic drug Stories

2008-09-24 09:00:13

BRIDGEWATER, N.J., Sept. 24 /PRNewswire-FirstCall/ -- Tony Award-winning actor and Broadway star Ben Vereen is partnering with sanofi-aventis, a world leader in diabetes care, to launch Take the Stage for Diabetes Awareness, a national awareness campaign designed to educate people living with diabetes about their condition. Since he was diagnosed with type 2 diabetes in 2007, Mr. Vereen has worked hard to manage his condition and is now urging others living with diabetes to work with their...

81b416161e923b00423da283a2c463d21
2008-09-24 08:39:04

A team of researchers has identified the active compounds that contribute to the health benefits of pre-germinated brown rice; the healthy components are a related set of sterol-like molecules known as acylated steryl-beta-glucosides (ASGs). Pre-germinated rice (PR) is an emerging health food whereby brown rice is soaked in warm water prior to cooking; the warm bath induces germination, or sprouting, which stimulates rice enzymes to produce more nutrients. One such nutrient is the important...

2008-09-22 06:00:30

Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced the initiation of the next phase of the preclinical safety program for AKP-020. While an analysis of the one-month preclinical safety studies is ongoing, the company has initiated a three-month preclinical safety program in order to support further clinical evaluation of its product. Combined with the thorough analysis of the recent Phase IIa study of AKP-020 in diabetic subjects, the...

2008-09-16 06:00:10

GI Dynamics, a medical device company pioneering the development of new approaches to treat metabolic disorders, today announced new data regarding the EndoBarrier(TM), its novel, noninvasive device currently in clinical trials to treat obesity and type 2 diabetes. New data from a pilot clinical trial indicate that patients with uncontrolled type 2 diabetes using the EndoBarrier Gastrointestinal Liner achieved a statistically significant improvement of glycemic control in just one week as...

2008-09-09 06:00:09

Results from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA(TM) (saxagliptin), an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), when used in combination with metformin as an initial therapy, produced significant reductions across all key measures of glucose...

2008-09-08 09:00:08

Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA(TM) (saxagliptin), an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions across all key measures of glucose control studied (glycosylated hemoglobin level (A1C), fasting...

2008-08-19 09:01:12

PALO ALTO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Telik, Inc. announced today that it has entered into a license agreement with ReceptorBio, Inc. which would enable ReceptorBio to develop and commercialize Telik's oral small molecule insulin receptor activators. These compounds were identified through the application of TRAP(R), Telik's proprietary drug discovery technology. The agreement provides for payments related to regulatory milestones and royalties based on product sales....

2008-08-19 09:01:12

FOSTER CITY, Calif., Aug. 19 /PRNewswire-FirstCall/ -- ReceptorBio, Inc. announced today that it has entered into a license agreement with Telik, Inc. (Palo Alto, CA) that would enable ReceptorBio to develop and commercialize Telik's unique, oral small molecule insulin receptor activators. These compounds were identified through the application of TRAP(R), Telik's proprietary drug discovery technology. The agreement provides for payments related to regulatory milestones and royalties based...

2008-08-13 15:01:02

A wrongful death suit was filed against GlaxoSmithKline, SmithKline Beecham, and McKesson Corporation in California Superior Court, charging that Avandia, prescribed for Type 2 Diabetes, led to heart attacks, congestive heart failure and other fatal cardiovascular injuries in seven individuals. The suit, brought by Khorrami, Pollard & Abir and Kabateck Brown Kellner, LLP, was filed on behalf of the victims' seven surviving spouses, including Los Angeles, CA, and Costa Mesa, CA,...

2008-08-11 09:01:40

DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and clinical development company focused on a novel approach to treating type 2 diabetes, today announces enrollment of the first patient in the phase II proof of concept clinical trial with DM-99, the Company's third drug candidate to enter phase II human trials. The single-blinded clinical trial being conducted in the European Union, will demonstrate DM-99's effectiveness at controlling blood glucose levels in 40 type 2 diabetes patients...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related